ZIVO Bioscience Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

ZIVO Bioscience wird ein Gewinn- und Umsatzwachstum von 18.1% bzw. 135.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 61% pro Jahr wachsen soll.

Wichtige Informationen

18.1%

Wachstumsrate der Gewinne

61.0%

EPS-Wachstumsrate

Personal Products Gewinnwachstum	23.2%
Wachstumsrate der Einnahmen	135.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	04 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

ZIVO Bioscience: Building An IP Portfolio For Algal Biomass Derived Ingredients

Nov 25

Gewinn- und Umsatzwachstumsprognosen

OTCPK:ZIVO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	2	-5	N/A	N/A	1
12/31/2024	0	-6	N/A	N/A	1
3/31/2024	0	-7	-5	-5	N/A
12/31/2023	0	-8	-6	-6	N/A
9/30/2023	0	-9	-7	-7	N/A
6/30/2023	0	-9	-6	-6	N/A
3/31/2023	N/A	-9	-6	-6	N/A
12/31/2022	N/A	-9	-7	-7	N/A
9/30/2022	N/A	-9	-8	-8	N/A
6/30/2022	N/A	-9	-8	-8	N/A
3/31/2022	N/A	-9	-9	-9	N/A
12/31/2021	N/A	-9	-7	-7	N/A
9/30/2021	N/A	-7	-6	-6	N/A
6/30/2021	N/A	-9	-5	-5	N/A
3/31/2021	N/A	-9	-3	-3	N/A
12/31/2020	0	-9	-3	-3	N/A
9/30/2020	0	-11	-2	-2	N/A
6/30/2020	0	-10	-3	-3	N/A
3/31/2020	0	-11	-4	-4	N/A
12/31/2019	N/A	-12	-4	-4	N/A
9/30/2019	N/A	-10	-4	-4	N/A
6/30/2019	N/A	-13	-4	-4	N/A
3/31/2019	N/A	-14	-5	-5	N/A
12/31/2018	N/A	-15	-5	-5	N/A
9/30/2018	N/A	-15	-5	-5	N/A
6/30/2018	N/A	-14	-5	-5	N/A
3/31/2018	N/A	-12	-5	-5	N/A
12/31/2017	N/A	-10	N/A	-4	N/A
9/30/2017	N/A	-7	N/A	-4	N/A
6/30/2017	N/A	-6	N/A	-3	N/A
3/31/2017	N/A	-7	N/A	-2	N/A
12/31/2016	N/A	-6	N/A	-3	N/A
9/30/2016	N/A	-6	N/A	-2	N/A
6/30/2016	N/A	-6	N/A	-2	N/A
3/31/2016	N/A	-6	N/A	-3	N/A
12/31/2015	N/A	-6	N/A	-2	N/A
9/30/2015	N/A	-4	N/A	-2	N/A
6/30/2015	N/A	-6	N/A	-3	N/A
3/31/2015	N/A	-5	N/A	-2	N/A
12/31/2014	N/A	1	N/A	-3	N/A
9/30/2014	N/A	0	N/A	-3	N/A
6/30/2014	N/A	-1	N/A	-3	N/A
3/31/2014	N/A	-5	N/A	-3	N/A
12/31/2013	N/A	-10	N/A	-3	N/A
9/30/2013	N/A	-11	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ZIVO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ZIVO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ZIVO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ZIVODie Einnahmen des Unternehmens (117.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: ZIVODie Einnahmen des Unternehmens (117.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ZIVO in 3 Jahren voraussichtlich hoch sein wird

ZIVO Bioscience Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024

The Nasdaq Stock Market to Delist the Common Stock of ZIVO Bioscience

ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study

Zivo Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

ZIVO Bioscience, Inc. announced that it has received $0.531142 million in funding

Nasdaq Determines to Delist the ZIVO Bioscience's Common Stock from the Nasdaq Capital Market

Nasdaq Determines to Delist the ZIVO Bioscience's Common Stock from the Nasdaq Capital Market

New major risk - Share price stability

ZIVO Bioscience Announces Reverse Stock Split to Regain Compliance with the Nasdaq Stock Market’s Continued Listing Requirements

New major risk - Market cap size

Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Nasdaq Hearings Panel Grants Zivo Biosciences's Request to Provide an Extension Until November 20, 2023 to Regain Compliance with the Stockholders’ Equity Rule for Continued Listing on Nasdaq

New minor risk - Shareholder dilution

Zivo Bioscience, Inc. Announces its GRAS Designation Reaffirmed for Proprietary Algal Biomass Product as Human Food Ingredient

Nasdaq Notifies Zivo Biosciences Regarding its Common Stock Delisting from Nasdaq Due to Non-Compliance with the Stockholders’ Equity Requirement

ZIVO Bioscience, Inc. Announces Results of Study with Its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Independent Director recently bought US$72k worth of stock

Zivo Bioscience Receives Written Notice from the Nasdaq Stock Market

ZIVO Bioscience, Inc. Reports USDA Claims Regulatory Jurisdiction for New Coccidiosis Treatment

ZIVO Bioscience, Inc., Annual General Meeting, Jul 28, 2022

ZIVO Bioscience Regains Compliance Following Receipt of Non-Compliance Notice from Nasdaq

ZIVO Bioscience, Inc. announced delayed annual 10-K filing

Independent Director recently bought US$340k worth of stock

ZIVO Bioscience: Building An IP Portfolio For Algal Biomass Derived Ingredients

Independent Director Robert Rondeau has left the company

ZIVO Bioscience, Inc. has completed a Composite Units Offering in the amount of $13.8 million.

ZIVO Bioscience, Inc. Announces Us Patent Office Notice of Allowance for Administration of Proprietary Algal Biomass to Support Immune Health

ZIVO Bioscience, Inc. Appoints Alison A. Cornell as Member of the Board

ZIVO Bioscience, Inc. Announces Executive Changes

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken